- Home
- PNI vs WHWK Comparison
PNI vs WHWK Comparison
Compare PNI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- WHWK
- Stock Information
- Founded
- PNI 2002
- WHWK 2007
- Country
- PNI United States
- WHWK United States
- Employees
- PNI N/A
- WHWK N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- WHWK Health Care
- Exchange
- PNI Nasdaq
- WHWK Nasdaq
- Market Cap
- PNI 77.2M
- WHWK 82.4M
- IPO Year
- PNI N/A
- WHWK N/A
- Fundamental
- Price
- PNI $6.95
- WHWK $1.95
- Analyst Decision
- PNI
- WHWK
- Analyst Count
- PNI 0
- WHWK 0
- Target Price
- PNI N/A
- WHWK N/A
- AVG Volume (30 Days)
- PNI 26.4K
- WHWK 122.8K
- Earning Date
- PNI 01-01-0001
- WHWK 11-15-2025
- Dividend Yield
- PNI 4.76%
- WHWK N/A
- EPS Growth
- PNI N/A
- WHWK N/A
- EPS
- PNI N/A
- WHWK N/A
- Revenue
- PNI N/A
- WHWK $21,596,000.00
- Revenue This Year
- PNI N/A
- WHWK N/A
- Revenue Next Year
- PNI N/A
- WHWK N/A
- P/E Ratio
- PNI N/A
- WHWK N/A
- Revenue Growth
- PNI N/A
- WHWK N/A
- 52 Week Low
- PNI $6.03
- WHWK $1.39
- 52 Week High
- PNI $7.89
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- PNI 73.75
- WHWK 59.78
- Support Level
- PNI $6.49
- WHWK $1.80
- Resistance Level
- PNI $6.93
- WHWK $2.02
- Average True Range (ATR)
- PNI 0.07
- WHWK 0.10
- MACD
- PNI 0.03
- WHWK 0.02
- Stochastic Oscillator
- PNI 90.49
- WHWK 67.86
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.